Schlaganfall: Pharmakologische Prävention
Über den Vortrag
Der Vortrag „Schlaganfall: Pharmakologische Prävention“ von Roy Strowd, MD ist Bestandteil des Kurses „Ischämischer Schlaganfall und intrakranielle Blutungen“.
Quiz zum Vortrag
What is primary stroke prevention?
- Measures to reduce the risk of stroke in individuals with no history of stroke but who are at high risk for stroke
- Treatment of individuals who have had a stroke or a TIA and are at risk for a future event
- Large-scale prevention of stroke at a population level
- The use of pharmacologic therapy to prevent stroke
- The implementation of lifestyle modifications to prevent stroke
Which of the following is NOT an antiplatelet medication used to prevent strokes?
- Heparin
- Aspirin
- Clopidogrel
- Ticagrelor
- Dipyridamole
What is the advantage of direct oral anticoagulants (DOACs) over warfarin?
- There is no need for frequent monitoring and there are fewer drug-drug interactions.
- Warfarin requires dosing multiple times a day.
- DOACs require only once-weekly dosing.
- There is no significant difference between the two agents.
If a patient were to present with a watershed infarct, which therapeutic intervention would be the most appropriate?
- IV fluids
- Aspirin
- Clopidogrel
- Warfarin
- Low-molecular-weight heparin
What is the mechanism of action of clopidogrel?
- It is a P2Y12 inhibitor that blocks ADP receptors.
- It is a COX and thromboxane A2 inhibitor.
- It increases plasma adenosine.
- It increases platelet phosphodiesterase.
- It increases platelet aggregation.
What are some of the common side effects of aspirin and extended-release dipyridamole (ASA–ERDP)?
- Headache and GI upset
- Fevers and hepatosplenomegaly
- Lymphadenopathy and GI bleeding
- Nausea and serum sickness reaction
- Myalgias and LFT elevations
What is the major side effect to consider in patients taking dual antiplatelet therapy?
- Increased risk of CNS and systemic bleeding
- Increased risk of LFT elevations
- Pulmonary toxicity
- Hypothyroidism
- Increased risk of myocardial infarction
What is the mechanism of action of cilostazol?
- Phosphodiesterase inhibitor
- P2Y12 inhibitor
- TXA2 inhibitor
- COX inhibitor
- Leukotriene inhibitor
Diese Kurse könnten Sie interessieren
Dozent des Vortrages Schlaganfall: Pharmakologische Prävention
Roy Strowd, MD
Dr. Roy Strowd is the Assistant Dean of Undergraduate Medical Education at the Wake Forest Baptist Medical Center, in North Carolina, USA.
He obtained his MD from Wake Forest School of Medicine in 2009, and his MEd from Johns Hopkins University in 2021. Currently, he co-directs the Neurofibromatosis and Tuberous Sclerosis Clinics at Wake Forest Baptist Medical Center, and is a researcher for the Adult Brain Tumor Consortium (ABTC) and Alliance for Clinical Trials in Neuro-Oncology.
Due to his achievements, he earned the M. Brownell Anderson Award from the Association of American Medical Colleges.
Within Lecturio, Dr. Strowd teaches courses on Clinical Neurology.
Kundenrezensionen
5,0 von 5 Sternen
| 5 Sterne |
|
5 |
| 4 Sterne |
|
0 |
| 3 Sterne |
|
0 |
| 2 Sterne |
|
0 |
| 1 Stern |
|
0 |
